What You Should Know

• Healthcare intelligence leader Health Catalyst has signed a definitive agreement to divest its mid-revenue cycle business unit, Vitalware, LLC, to Med-Metrix for $147M in cash.
• The transaction allows Health Catalyst to shed a non-core financial software asset and sharpen its corporate focus on driving cost, clinical, and consumer performance improvements.
• The $147M cash injection, combined with existing capital, will be deployed to fully repay and terminate Health Catalyst’s $160 million senior secured term loan facility.
• Vitalware is a recognized mid-revenue cycle leader that generated approximately $37 million in revenue during fiscal year 2025.
• The corporate separation frees up long-term financial flexibility, allowing Health Catalyst to accelerate its core technology and healthcare AI roadmap.

Focus Over Fragmentation: Why Health Catalyst Is Divesting Vitalware for $147M

The healthcare technology and enterprise software landscape is working through an intensive phase of structural realignment. Over the past decade, many digital health vendors sought to build expansive, multi-categorical platforms by acquiring adjacent software business units across clinical, operational, and financial silos. However, running a highly fragmented portfolio often dilutes an organization’s core engineering focus and ties up valuable capital in distinct software categories that require separate research and development pipelines.

In a macroeconomic market that increasingly penalizes operational complexity, healthcare leaders are realizing that enterprise success requires deep domain conviction rather than broad, disconnected offerings. For technology provider organizations, long-term sustainability means shedding non-core business segments to maximize capital flexibility, clear outstanding debt, and aggressively fund specialized artificial intelligence frameworks that return immediate, measurable value to customers.

To streamline its operational profile and fully back its long-term corporate roadmap, healthcare intelligence pioneer Health Catalyst, Inc. has announced a definitive agreement to divest Vitalware, LLC and its associated mid-revenue cycle business unit. The business will be acquired by technology-enabled revenue cycle specialist Med-Metrix for a total consideration of $147M in cash. Expected to close in 2026 pending standard regulatory waiting periods, the transaction represents a calculated corporate pivot designed to accelerate Health Catalyst’s core clinical transformation.

Deleveraging the Balance Sheet to Accelerate the Core AI Roadmap

Vitalware by Health Catalyst has long operated as a highly respected suite of mid-revenue cycle solutions, providing hospitals with specialized data models and applied AI to manage coding compliance, chargemaster tasks, charge capture, and federal price transparency rules. The business unit achieved best-in-KLAS status and captured approximately $37 million in revenue during fiscal year 2025. Yet, financial operations represent an administrative category entirely distinct from the data-driven clinical and operational improvement initiatives that form the historical identity of Health Catalyst’s platform.

By divesting this segment to Med-Metrix—a company explicitly structured to invest deeply in dedicated revenue cycle management—Health Catalyst immediately strengthens its financial flexibility. The company plans to merge the $147 million in net cash proceeds with existing cash on hand to fully repay and terminate its outstanding senior secured term loan facility. This financial maneuver wipes out approximately $160 million in outstanding principal debt as of March 31, 2026, alongside associated interest obligations and prepayment costs, structurally cleaning the corporate balance sheet.

Ben Albert, CEO of Health Catalyst, highlighted the strategic necessity of the transaction, calling it a significant step forward for the enterprise. Albert noted that by concentrating the business precisely around the clinical environments where they maintain the deepest conviction, the company can deploy a lean capital structure optimized to sustain its long-term growth priorities.

Monetizing a Moat of $2.8 Billion in Documented Outcomes

Once free of its legacy debt obligations, Health Catalyst’s core strategy will focus heavily on scaling its proprietary healthcare improvement data engine. Built on 18 years of historical tracking and backed by $2.8 billion in validated, documented outcomes, this core platform allows health systems to move seamlessly from raw data silos to confident, prioritized actions. The freed-up capital will directly fund an aggressive, clinical AI roadmap designed to enable hospital networks to autonomously turn their localized data lakes into clear operational improvements across cost, clinical care, and consumer engagement performance.

To complete the transaction, Raymond James acted as the exclusive financial advisor to Health Catalyst, with Latham & Watkins LLP providing outside legal counsel. Additional statutory disclosures surrounding the cash divestiture have been filed via a Form 8-K with the Securities and Exchange Commission.